A few other antigens, such as CSPG4 (glycoprotein and chondroitin sulfate proteoglycan), MC1R (melanocortin receptor group), DR5 (death receptor 5), and MSCP (glycoprotein and chondroitin sulfate proteoglycan) are currently being explored as targets for bispecific antibodies treating melanoma [12]. This evidence concerns the gene CSPG4 and melanoma.